Sustainability is no longer a peripheral conversation in pharmaceutical packaging. It is becoming a strategic, regulatory and operational priority for pharmaceutical companies, contract manufacturers, packaging suppliers and marketing authorisation holders. Across Europe and the UK, organisations are under increasing pressure to reduce packaging waste, improve recyclability, use materials more efficiently and demonstrate responsible environmental practices.
However, in the pharmaceutical sector, packaging is never just packaging.
A carton, blister, bottle, vial, stopper, label or leaflet plays a direct role in protecting product quality, supporting patient safety, maintaining traceability and ensuring regulatory compliance. This is why Quality Assurance must be involved at the earliest possible stage of any packaging sustainability project. If QA is brought in only when a new material, format or supplier is ready for approval, the project may already carry unnecessary risk, delay and cost.
For pharmaceutical organisations, the challenge is not simply to make packaging more sustainable. The challenge is to do so without compromising the quality, safety, efficacy, stability or regulatory status of the product.
Sustainability Is Changing the Packaging Conversation
Recent regulatory developments have accelerated the focus on packaging sustainability. The EU Packaging and Packaging Waste Regulation introduces stronger expectations around packaging minimisation, recyclability, labelling, waste reduction and the circular use of materials. In the UK, Extended Producer Responsibility for packaging is also changing the way organisations account for the environmental impact and cost of packaging placed on the market.
These changes are pushing companies to review long-established packaging formats. Common initiatives may include reducing excess secondary packaging, moving to lighter materials, redesigning cartons, improving recyclability, reducing plastic use, changing inks or adhesives, increasing recycled content where appropriate, or working with suppliers that can provide more sustainable materials.
While these initiatives may appear straightforward from a sustainability or procurement perspective, each one can have quality implications. A lighter carton may affect transit performance. A new blister material may alter moisture protection. A different label adhesive may behave differently under cold-chain conditions. A recycled or alternative material may raise questions around extractables, leachables, contamination control or supplier qualification.
In pharmaceuticals, even small packaging changes can create significant downstream consequences.
Why QA Must Be Involved from the Start
Quality Assurance brings a risk-based view that is essential when evaluating packaging sustainability options. Early QA involvement helps ensure that environmental goals are assessed alongside GMP obligations, product requirements, patient safety expectations and regulatory commitments.
A robust QA-led review should ask practical questions such as:
- Is the proposed packaging change related to primary, secondary or tertiary packaging?
- Could the change affect product stability, sterility, integrity, identification or usability?
- Does the new material have appropriate specifications, certificates and supplier controls?
- Is additional testing required, such as stability, compatibility, transport validation or container closure integrity testing?
- Could the change affect approved artwork, labelling text, readability or patient information?
- Is the change notifiable to regulators, or does it require a variation?
- Does the change affect batch release, QP responsibilities or product quality review data?
- Are complaints, deviations, or recalls more likely if the change is poorly implemented?
These questions should not be left until the end of the project. They should shape the project from the beginning.
The Risk of Treating Sustainability as a Procurement Exercise
One of the most common mistakes organisations can make is treating sustainable packaging as a sourcing or cost-saving project rather than a quality-critical change. Procurement, sustainability and supply chain teams may identify a material that is cheaper, lighter, recyclable or easier to source. Yet without QA input, the organisation may overlook how that material performs across the full product lifecycle.
Packaging must protect the medicine from manufacture through storage, distribution, dispensing and patient use. This includes protection from moisture, oxygen, light, microbial contamination, mechanical damage and mix-ups. It also includes ensuring that labelling remains legible, tamper-evident features function as intended, and instructions for use remain clear.
A sustainable material that fails to protect the product is not a sustainable solution. It simply transfers environmental progress into quality risk.
Change Control Is the Bridge Between Innovation and Compliance
Sustainable packaging innovation should be encouraged, but it must be managed through a disciplined change control process. QA plays a central role in ensuring that proposed changes are assessed, documented, justified, approved and verified before implementation.
A strong change control process should include a clear change rationale, quality risk assessment, regulatory impact assessment, supplier qualification review, validation or verification requirements, implementation plan, artwork review, stock transition strategy, and post-implementation monitoring.
This is particularly important where packaging changes affect approved dossiers, registered specifications or product information. In these cases, regulatory affairs and QA must work closely together to determine whether a variation, notification or prior approval is required before the change can be introduced.
The best organisations do not see change control as an administrative barrier. They see it as a framework that allows innovation to happen safely.
Supplier Qualification Matters More Than Ever
As demand for sustainable packaging grows, pharmaceutical companies may find themselves working with new suppliers, new material streams or new manufacturing processes. This makes supplier qualification and ongoing supplier oversight essential.
QA should assess whether suppliers can provide consistent material quality, appropriate GMP or quality system controls, traceability, change notification commitments and reliable technical documentation. Sustainability claims should also be verified rather than accepted at face value. For example, claims around recyclability, recycled content, compostability, or reduced carbon impact should be supported by appropriate evidence.
For pharmaceutical companies, supplier changes are rarely low-risk. A supplier’s sustainability credentials must be balanced with their ability to meet pharmaceutical quality expectations.
Stability, Compatibility and Patient Use Cannot Be Assumed
Packaging changes may require additional testing depending on the nature of the product and the proposed change. For example, changes to primary packaging materials may require stability studies, compatibility assessments, extractables and leachables evaluation, container closure integrity testing or shipping validation.
Secondary packaging changes may still require testing if they affect protection during transport, temperature control, tamper evidence, serialisation, readability or the patient experience. Even a change to carton size or leaflet format can have practical implications for pharmacists, healthcare professionals and patients.
QA must help determine what evidence is needed to demonstrate that the sustainable packaging option remains fit for purpose.
Early QA Involvement Prevents Late-Stage Delays
When QA is engaged too late, sustainability projects can stall. Teams may discover that a preferred material lacks sufficient documentation, a supplier has not been qualified, a regulatory submission is required, or validation work has not been planned. These issues can lead to project delays, increased costs, rejected batches, market supply risks or difficult conversations with regulators.
Early QA involvement helps avoid these problems by identifying critical quality requirements before decisions are made. It also helps cross-functional teams make better choices from the outset.
In practice, sustainable packaging projects should involve QA, regulatory affairs, supply chain, procurement, manufacturing, engineering, artwork, validation, qualified persons and sustainability leads. The earlier these groups collaborate, the more likely the organisation is to achieve both environmental and compliance objectives.
QA as a Strategic Partner in Sustainable Packaging
The role of QA is evolving. Quality professionals are no longer simply reviewing documentation at the end of a project. They are strategic partners who help organisations innovate responsibly.
In sustainable packaging, QA provides the structure, challenge and evidence-based thinking needed to ensure that changes are scientifically justified and properly controlled. This is especially important in a sector where patient safety must remain the primary obligation.
For pharmaceutical companies, the message is clear: sustainability and quality are not competing priorities. When managed correctly, they can reinforce each other. Sustainable packaging changes can reduce waste, improve efficiency and support corporate responsibility, but only when they are introduced through robust quality systems and risk-based decision-making.
Final Thought
The future of pharmaceutical packaging will be more sustainable, more scrutinised and more complex. Organisations that involve QA, and QA Resources, early will be better positioned to manage that complexity, meet regulatory expectations and protect patients.
Packaging changes for sustainability should not begin with the question, “Can we make this greener?” They should begin with a more complete question: “How can we make this greener while maintaining quality, compliance and patient safety?”
That is where Quality Assurance must lead.